Liver-related outcomes of MASLD patients in a prospective, German real-world cohort
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e667
DOI: 10.1055/s-0044-1789801 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von M. Rau und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Metabolic dysfunction associated steatotic liver disease (MASLD) is the most frequent chronic liver disease with rising prevalence. Longitudinal data of clinical outcomes in MASLD patients are scarce and in Germany currently lacking. The aim of this study is to analyse the MASLD disease course focusing on liver-related outcomes in a prospective, German real-world cohort.
Methods
Between 3/2012-12/2023, 288 MASLD patients without bariatric intervention were characterized either by histology, Fibroscan or sonography and prospectively followed in an observational single-center study at a tertiary centre. Liver-related outcomes were analysed over the study period. Statistical analyses were conducted using SPSS.
Results
A total of 288 MASLD patients were followed for a median of 37±33 (IQR 21-54) months. All patients fulfilled the criteria of the new MASLD nomenclature. Slightly more men (54.5%) were included, mean age was 51.8 years, with a mean BMI of 32.5±6.5kg/m 2 . Among the patients, 36% were histologically diagnosed, (of those 24.0% MASH, 36.9% had significant fibrosis F2-F4 upon inclusion), 59% were staged by elastography (11.7% with liver stiffness (LS) 8-12kPa and 20.5% with >12kPa equivalent to fibrosis stages F2-3 and F4, respectively) and 5% were diagnosed clinically/sonographically. Additionally, 38% of patients had T2DM, 56% arterial hypertension, 36% hypercholesterinemia, and 12% hypertriglyceridemia. Longterm FU data showed that patients with cirrhosis (histology or LS) had significantly more liver-related outcomes compared to patients without cirrhosis (HR 3.501 (95%-CI 1.835-6.682), p 12kPa with highest rate of liver-related outcomes in the group of >12kPa (HR 4.63 (95%-CI 1.51-14.16), p=.007 and HR 11.738 (95%-CI 4.421-31.167), p
Zitieren
APA
Rau, M., Kestel, J., Monte, S. D., Leicht, H. B., Reiter, F. P., Hermanns, H., & Geier, A. (2024). Liver-related outcomes of MASLD patients in a prospective, German real-world cohort. Zeitschrift für Gastroenterologie, 62(09), e667. https://doi.org/10.1055/s-0044-1789801
Vancouver
Rau M, Kestel J, Monte SD, Leicht HB, Reiter FP, Hermanns H, et al. Liver-related outcomes of MASLD patients in a prospective, German real-world cohort. Zeitschrift für Gastroenterologie. 2024;62(09):e667. doi:10.1055/s-0044-1789801
BibTeX
@article{Rau2024,
author = {Rau, M. and Kestel, J. and Monte, S. De and Leicht, H. B. and Reiter, F. P. and Hermanns, H. and Geier, A.},
title = {Liver-related outcomes of MASLD patients in a prospective, German real-world cohort},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {e667},
doi = {10.1055/s-0044-1789801}
}
EUVIMED